Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (101-110 of 1,111) with videos related to

Pageof 112
Sort By:
Emergency Radiology|January 15, 2011
Myocardial infarction after blunt chest trauma: usefulness of cardiac ECG-gated CT and MRI for positive and aetiologic diagnosisGregory Malbranque, Jean Michel Serfaty, Dominique Himbert, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Thrombosis and Haemostasis|April 8, 2009
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarctionMarie-Geneviève Huisse, Nadine Ajzenberg, Laurent Feldman, et al.
BMC Medical Research Methodology|April 3, 2016
On the use of propensity scores in case of rare exposureDavid Hajage, Florence Tubach, Philippe Gabriel Steg, et al.
Wiener Klinische Wochenschrift|September 16, 2017
Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registryIrene M Lang, Roza Badr-Eslam, Nicola Greenlaw, et al.
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
American Heart Journal|June 22, 2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gapDimitrios Alexopoulos, Deepak L Bhatt, Chistian W Hamm, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American Heart Association|July 2, 2021
Cangrelor: Clinical Data, Contemporary Use, and Future PerspectivesLeonardo De Luca, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Pageof 112

Showing results (101-110 of 1,111) with videos related to

Sort By:
Pageof 112
Emergency Radiology|January 15, 2011
Myocardial infarction after blunt chest trauma: usefulness of cardiac ECG-gated CT and MRI for positive and aetiologic diagnosisGregory Malbranque, Jean Michel Serfaty, Dominique Himbert, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Thrombosis and Haemostasis|April 8, 2009
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarctionMarie-Geneviève Huisse, Nadine Ajzenberg, Laurent Feldman, et al.
BMC Medical Research Methodology|April 3, 2016
On the use of propensity scores in case of rare exposureDavid Hajage, Florence Tubach, Philippe Gabriel Steg, et al.
Wiener Klinische Wochenschrift|September 16, 2017
Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registryIrene M Lang, Roza Badr-Eslam, Nicola Greenlaw, et al.
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
American Heart Journal|June 22, 2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gapDimitrios Alexopoulos, Deepak L Bhatt, Chistian W Hamm, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American Heart Association|July 2, 2021
Cangrelor: Clinical Data, Contemporary Use, and Future PerspectivesLeonardo De Luca, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Pageof 112